SANUWAVE Health, Inc. (SNWV) shares are trading lower by 5% on Friday, even after the company reported preliminary second-quarter results that came in above the high end of its revised guidance. It's one of those moments where the numbers look good, but the market is focused on the bigger picture.

The Numbers

Sanuwave expects Q2 2026 revenue to land between $9.6 million and $9.8 million. That's above the high end of its previous guidance range of $8.5 million to $9.5 million. But compared to the same quarter last year, revenue is down about 3% to 5% from the $10.1 million reported in Q2 2025.

CEO Morgan Frank said the quarter's revenue exceeded the upper end of the company's June guidance, and overall performance was largely in line with expectations. That's the kind of language that suggests management is cautiously optimistic, but not popping champagne.

The Headwinds

The main drag on the business right now is capital sales. Customers are facing financial constraints, and there's a growing market for used UltraMIST systems, which makes it harder to sell new ones. To counter that, Sanuwave is supporting new users through qualification, training, and service programs, and offering trade-in options for certified pre-owned systems that come with manufacturer warranties.

On the bright side, consumable applicator sales hit record highs in both units sold and revenue. That's the kind of recurring revenue stream that investors love to see, because it suggests that once a hospital or clinic buys the system, they keep using it and buying the disposables.

The Business Model

SANUWAVE Health is a medical device company that sells directed energy products for wound care. Its flagship product is the UltraMIST system, an FDA-cleared device that uses noninvasive ultrasound to trigger a biological response that supports tissue repair and regeneration. Think of it as a high-tech way to help stubborn wounds heal.

The company operates in a single reportable segment—design and sale of medical devices—and generates most of its revenue in the United States. For a single-product-focused med-tech company, sales traction is the clearest near-term read on adoption, even if the stock chart is still signaling a longer-term downtrend.

The MarketDash Edge Scorecard

Here's how SANUWAVE Health stacks up on the MarketDash Edge scorecard, which compares it to the broader market:

• Momentum: Weak (Score: 0.61) — The stock is showing extremely weak trend strength, which lines up with its position below key moving averages. This is the main reason the stock isn't rallying on good news.
• Value: Neutral (Score: 46.16) — The valuation profile is middle-of-the-road. Price action is likely being driven more by trend and execution than by whether the stock looks cheap or expensive.
• Growth: Strong (Score: 99.28) — The model is flagging strong growth characteristics, which fits with the market focusing on revenue updates like the preliminary Q2 range.

The Verdict: SANUWAVE Health's Edge signal reveals a growth-tilted profile that's being overshadowed by very weak momentum. For longer-term bulls, the setup improves if revenue strength starts to translate into sustained trend reversals on the chart, starting with reclaiming the 20-day and 50-day moving averages.

Price Action

Sanuwave shares were trading down 4.44% at $6.36 at the time of publication on Friday, according to market data.